Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 4/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 6/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15798497 | 0.70 | ALDH1A1 (0.62) | ALDH1A1KDM4EGLAKMT2AHTT | |
| SCHEMBL9537153 | 0.70 | ALDH1A1 (0.62) | ALDH1A1KDM4EGLAKMT2AHTT | |
| SCHEMBL1029816 | 0.67 | KMT2A (0.43) | ALDH1A1KDM4EGLAKMT2AHTT | |
| SCHEMBL15075712 | 0.66 | MAPT (0.44) | ALDH1A1KDM4EGLAKMT2AHTT | |
| SCHEMBL15384246 | 0.66 | ALDH1A1 (0.41) | ALDH1A1KDM4EGLAKMT2AHTT | |
| SCHEMBL9539146 | 0.65 | ALDH1A1 (0.64) | ALDH1A1KDM4EGLAKMT2AHTT | |
| SCHEMBL476164 | 0.65 | ALDH1A1 (0.51) | ALDH1A1KDM4EGLAKMT2AHTT | |
| SCHEMBL4519253 | 0.63 | ALDH1A1 (0.50) | ALDH1A1KDM4EGLAKMT2AHTT | |
| SCHEMBL12322876 | 0.62 | MAPT (0.52) | ALDH1A1KDM4EGLAKMT2AHTT | |
| SCHEMBL19036686 | 0.62 | RXFP1 (0.39) | ALDH1A1KDM4EGLAKMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180133170-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | ELI LILLY AND COMPANY | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133170-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | TRPA1, TRPV1, TRPV3 | ALDH1A1 968/4885KDM4E 4704/4885GLA 3504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.